Human orthopneumovirus

Karyopharm Announces Selinexor Clinical Data to be Presented at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19

Retrieved on: 
Tuesday, October 6, 2020
Antineoplastic drugs, Clinical medicine, Medicine, Chemical compounds, Selective inhibitor of nuclear export, XPO1, Selinexor, RNA virus, Human orthopneumovirus, Virus, RSV, SINE

The presentation will feature data from a Phase 2 clinical study evaluating low dose oral selinexor in hospitalized patients with severe COVID-19 (NCT04349098).

Key Points: 
  • The presentation will feature data from a Phase 2 clinical study evaluating low dose oral selinexor in hospitalized patients with severe COVID-19 (NCT04349098).
  • XPO1 inhibitors, including selinexor, have demonstrated activity against over 20 different viruses, including the RNA viruses, influenza, respiratory syncytial virus (RSV) and other common causes of respiratory infection.
  • Details for the ISIRV-AVG oral presentation are as follows:
    XPOVIO is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound.
  • XPOVIO functions by selectively binding to and inhibiting the nuclear export protein exportin 1 (XPO1, also called CRM1).

BioGX launches CE-IVD Marked COVID-19, Influenza A/B, RSV Combo RT-PCR Test for the BD MAX™ System

Retrieved on: 
Tuesday, September 29, 2020
Infectious diseases, Medical specialties, Health, BD, Franklin Lakes, New Jersey, Influenza, Human orthopneumovirus

AMSTERDAM, Sept. 29,2020 /PRNewswire/ --BioGX BV, the European subsidiary of Birmingham, Alabama based BioGX, announced availability of a CE-IVD marked test for simultaneous detection of SARS-CoV-2, Influenza A, Influenza B and Respiratory Syncytial Virus RNA in a patient sample using the BD MAX System.

Key Points: 
  • AMSTERDAM, Sept. 29,2020 /PRNewswire/ --BioGX BV, the European subsidiary of Birmingham, Alabama based BioGX, announced availability of a CE-IVD marked test for simultaneous detection of SARS-CoV-2, Influenza A, Influenza B and Respiratory Syncytial Virus RNA in a patient sample using the BD MAX System.
  • BioGX provided tube snaps into a test-specific position on the BD MAX total nucleic acid extraction cartridge enabling Sample-to-Answer molecular testing.
  • The BD MAX System, commercialized by BD (Becton, Dickinson and Company), is a fully integrated and automated molecular diagnostic platform already in use at thousands of laboratories worldwide.
  • The BioGX COVID-19, Flu A, Flu B, RSV test is marketed and sold through BioGX BV's Global Distribution Network as CE-IVD marked for In Vitro Diagnostic Use.

BioGX launches CE-IVD Marked COVID-19, Influenza A/B, RSV Combo RT-PCR Test for the BD MAX™ System

Retrieved on: 
Tuesday, September 29, 2020
Infectious diseases, Medical specialties, Health, BD, Franklin Lakes, New Jersey, Influenza, Human orthopneumovirus

AMSTERDAM, Sept. 29,2020 /PRNewswire/ --BioGX BV, the European subsidiary of Birmingham, Alabama based BioGX, announced availability of a CE-IVD marked test for simultaneous detection of SARS-CoV-2, Influenza A, Influenza B and Respiratory Syncytial Virus RNA in a patient sample using the BD MAX System.

Key Points: 
  • AMSTERDAM, Sept. 29,2020 /PRNewswire/ --BioGX BV, the European subsidiary of Birmingham, Alabama based BioGX, announced availability of a CE-IVD marked test for simultaneous detection of SARS-CoV-2, Influenza A, Influenza B and Respiratory Syncytial Virus RNA in a patient sample using the BD MAX System.
  • BioGX provided tube snaps into a test-specific position on the BD MAX total nucleic acid extraction cartridge enabling Sample-to-Answer molecular testing.
  • The BD MAX System, commercialized by BD (Becton, Dickinson and Company), is a fully integrated and automated molecular diagnostic platform already in use at thousands of laboratories worldwide.
  • The BioGX COVID-19, Flu A, Flu B, RSV test is marketed and sold through BioGX BV's Global Distribution Network as CE-IVD marked for In Vitro Diagnostic Use.

ReViral Raises $44 Million in Series C Financing

Retrieved on: 
Tuesday, August 25, 2020
FDA, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, RSV, Human orthopneumovirus, Medical specialties, Antivirals, Microbiology

ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV), today announced the close of a US $44 million Series C financing led by CR-CP Life Science Fund.

Key Points: 
  • ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV), today announced the close of a US $44 million Series C financing led by CR-CP Life Science Fund.
  • Jason Zhou M.D., CEO and Managing Director of CR-CP Life Science Fund, joins the ReViral Board of Directors.
  • We are delighted by the strong financial support from this leading syndicate of healthcare investors, and we welcome Jason to our Board, said Alex Sapir, CEO, ReViral.
  • ReViral has recently initiated two international multicentre Phase 2 clinical studies of sisunatovir in pediatric and adult high-risk patient populations.

Respiratory Syncytial Virus Infections - Pipeline Review, H1 2020 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 19, 2020
Health, Infectious diseases, Health, Medical specialties, Clinical medicine, Human orthopneumovirus, Paramyxoviridae, RSV, Virus, Respiratory syncytial virus vaccine, Book:Common viral infections

The "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides an overview of the Respiratory Syncytial Virus Infections (Infectious Disease) pipeline landscape.
  • The Respiratory Syncytial Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection

Retrieved on: 
Tuesday, August 4, 2020
FDA, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Medical specialties, Antivirals, Infectious diseases, Human orthopneumovirus, Paramyxoviridae, Antiviral drug, RSV, Drugs, Fast track, Lumicitabine, Respiratory syncytial virus vaccine

ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics that target respiratory syncytial virus (RSV), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sisunatovir for the treatment of patients with serious RSV infection.

Key Points: 
  • ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics that target respiratory syncytial virus (RSV), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sisunatovir for the treatment of patients with serious RSV infection.
  • We are very pleased that sisunatovir has received Fast Track designation for the treatment of serious RSV, a significant global health concern, said Alex Sapir, CEO, ReViral.
  • A drug candidate with Fast Track designation is eligible for greater access to the FDA for the purpose of expediting the drug product candidate's development, review, and potential approval.
  • ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics, with an initial focus on the treatment of respiratory syncytial virus (RSV).

Nirsevimab reduced respiratory syncytial virus infections requiring medical care in healthy premature infants in Phase 2b trial

Retrieved on: 
Thursday, July 30, 2020
Medical specialties, Infectious diseases, Clinical medicine, Health, RTT, Neonatology, Human orthopneumovirus, Paramyxoviridae, Bronchiolitis, Preterm birth, Respiratory tract infection, Lower respiratory tract infection

ET

Key Points: 
  • ET
    PARIS July 30, 2020 Detailed results from the positive Phase 2b trial for nirsevimab showed a significant reduction in medically attended lower respiratory tract infections (LRTI), mainly bronchiolitis and pneumonia, and hospitalizations caused by respiratory syncytial virus (RSV) in healthy preterm infants.
  • Nirsevimab offers the important potential to reduce hospitalizations and emergency department and in-office visits, which are a significant burden for healthcare systems.
  • Healthy preterm infants of 2935 weeks gestation were randomized (2:1) to receive a single intramuscular injection of nirsevimab or placebo.
  • With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Nirsevimab reduced respiratory syncytial virus infections (lower respiratory tract infections) requiring medical care in healthy premature infants in Phase 2b trial compared to placebo

Retrieved on: 
Thursday, July 30, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Medical specialties, RTT, Human orthopneumovirus, Paramyxoviridae, Preterm birth, RSV, Lower respiratory tract infection, Clinical medicine, Medicine

Detailed results from the positive Phase 2b trial for nirsevimab showed a significant reduction in medically attended lower respiratory tract infections (LRTI) and hospitalisations caused by respiratory syncytial virus (RSV) in healthy preterm infants.

Key Points: 
  • Detailed results from the positive Phase 2b trial for nirsevimab showed a significant reduction in medically attended lower respiratory tract infections (LRTI) and hospitalisations caused by respiratory syncytial virus (RSV) in healthy preterm infants.
  • On the primary endpoint, nirsevimab achieved a statistically significant 70.1% (95% CI: 52.3%-81.2%) reduction of medically attended RSV LRTI compared to placebo through 150 days post-dose.
  • On the secondary endpoint, nirsevimab achieved a 78.4% (95% CI: 51.9%-90.3%) relative reduction in the incidence of hospitalisations due to RSV LRTI compared to placebo through 150 days post-dose.
  • Most babies who are hospitalised from RSV are otherwise healthy with no prior complications,2 but currently these infants have no approved preventative option to protect them.

COVID-19 Impacts: Respiratory Syncytial Virus Diagnostics Market will Accelerate at a CAGR of almost 10% through 2020-2024 | Increase In Product Launches to Boost Growth | Technavio

Retrieved on: 
Tuesday, July 28, 2020
Medical Supplies, Infectious diseases, Sports, Hockey, Managed care, General Health, Pharmaceutical, Health, Science, Other Science, Companies, Industries, Business, Human orthopneumovirus, Paramyxoviridae, Thermo Fisher Scientific, Hoffmann-La Roche, Danaher Corporation

Our respiratory syncytial virus diagnostics market report covers the following areas:

Key Points: 
  • Our respiratory syncytial virus diagnostics market report covers the following areas:
    This study identifies technological advancements as one of the prime reasons driving the respiratory syncytial virus diagnostics market growth during the next few years.
  • We provide a detailed analysis of around 25 vendors operating in the respiratory syncytial virus diagnostics market, including some of the vendors such as Abbott Laboratories, Becton, Dickinson and Co., bioMrieux SA, Bio-Rad Laboratories Inc., Danaher Corp., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Quidel Corp., Seegene Inc., and Thermo Fisher Scientific Inc.
  • Backed with competitive intelligence and benchmarking, our research reports on the respiratory syncytial virus diagnostics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

IMV Updates Rapid Progress on COVID-19 Vaccine Program

Retrieved on: 
Tuesday, July 14, 2020
Research, Infectious diseases, Public policy, Government, Clinical trials, Healthcare reform, Biotechnology, Health, Pharmaceutical, Science, Virology, Vaccination, Vaccine, Human orthopneumovirus, Medical specialties, Branches of biology, Medicine

The rapid progress in target selection, the vaccine formulation, manufacturing and preclinical results so far not only demonstrate the potential of our delivery platform, but also build on our previously reported clinical data from a similarly designed vaccine against RSV, the respiratory syncytial virus, says Frederic Ors, Chief Executive Officer at IMV.

Key Points: 
  • The rapid progress in target selection, the vaccine formulation, manufacturing and preclinical results so far not only demonstrate the potential of our delivery platform, but also build on our previously reported clinical data from a similarly designed vaccine against RSV, the respiratory syncytial virus, says Frederic Ors, Chief Executive Officer at IMV.
  • Clinical results1 have shown our DPX-based vaccine against RSV demonstrated a unique ability to generate safe and long-lasting immune responses in older adults.
  • IMVs candidate vaccine, DPX-COVID-19, is based on IMVs first-in-class delivery platform that generates targeted and sustained immune response in vivo.
  • Since the Company announced the selection of its candidate vaccine on May 21st, the Company has made significant progress.